Shares of Apollo Hospitals Enterprise remained in focus on Thursday after the company reported strong Q4 FY26 earnings and shared key long-term guidance during its post-results concall, including the planned Apollo HealthTech demerger and listing by Q4 FY27.
The stock was trading at Rs 8,316, up 0.09% in early trade on Thursday after hitting a 52-week high of Rs 8,388 in the previous session following the earnings announcement. The company’s market capitalisation stood at around Rs 1.19 lakh crore.
Apollo Hospitals reported consolidated net profit of Rs 547.2 crore for Q4 FY26, up 33% year-on-year from Rs 412 crore in the corresponding quarter last year. The profit also came ahead of CNBC-TV18 poll estimates of Rs 452.5 crore.
Revenue from operations rose 18.1% YoY to Rs 6,606 crore from Rs 5,592 crore, while EBITDA increased 31.3% to Rs 1,011 crore. EBITDA margin expanded to 15.3% from 13.8% a year ago, supported by strong growth in healthcare services and improving operational efficiencies.
During the earnings concall, management said the Apollo HealthTech demerger and listing process is expected to be completed by Q4 FY27, with the business targeting an annualised revenue run rate of Rs 25,000 crore by that period.
Apollo 24/7 is expected to achieve breakeven excluding ESOP costs in Q1 FY27 and including ESOP costs by Q3 FY27, management added. Apollo HealthCo is also targeting an exit EBITDA margin of 6.5% to 7% by Q4 FY27, aided by private label growth and lower digital losses.
The company said the healthcare services business is expected to deliver mid-teen growth in FY27, while established hospital units are projected to improve margins by at least 100 basis points.
Management also guided that losses from new hospitals could remain in the Rs 140–150 crore range for FY27, with peak quarterly losses likely in Q2 as expansion investments continue.
Apollo Hospitals’ healthcare services revenue grew 16% in Q4 FY26, supported by a 7% rise in inpatient volumes, a 4% increase in pricing, and improved case mix. EBITDA margin of established units expanded 105 basis points year-on-year to 25.5%.
The company also continued expansion across diagnostics, clinics, dialysis centres, and digital healthcare operations during FY26, while AI-enabled auto-validation systems processed over 86 lakh tests across multiple specialties.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.